目前全球生物制药产业发展处于快速上升期,抗体药物、生物疫苗被认为是未来生物医药领域发展的“潜力股”。在4月26日举办的2016年大连国际DNA和基因组活动周论坛中,记者了解到,在“十三五”医药生物产业规划的推动下,我国抗体药物迎来发展机遇期,但在知识产权、检测标准、成本控制等方面仍受到制约,仍待大力创新,规范发展,实现产业转型升级。 At present, the global bio-pharmaceutical industry is in a period of rapid growth. Antibody drugs and biological vaccines are considered as “potential stocks” for the future development of biomedicine. In the 2016 Dalian International Forum on DNA and Genome Activity held on April 26, the reporter learned that with the promotion of the “13th Five-Year Plan” for the pharmaceutical bio-industry, there is an opportunity for the development of our country’s antibody drugs. However, at the Intellectual property rights, testing standards, cost control and other aspects are still subject to constraints, yet to be vigorously innovated, standardize development and achieve industrial restructuring and upgrading.